(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
IDF says up to 90% of Iran’s weapons industry could be hit within days - 2Italian court approves extradition to Germany of Ukrainian suspect in Nord Stream pipeline blast
- 3The 12 biggest space stories of 2025 — according to you
- 423 Most Amusing Messages At any point Sent Among Youngsters and Their Folks
- 5Sea level doesn’t rise at the same rate everywhere – we mapped where Antarctica’s ice melt would have the biggest impact
- Instructions to Discuss Successfully with Your Auto Collision Lawyer
- Five held on suspicion of planning attack on German Christmas market
- Bomb blast in packed Nigerian mosque kills five
- Latvia seeks emergency UN meeting over Russian missile attack on Lviv
- Flu cases spiking this holiday season, CDC data shows
- RSF attack on Sudan’s South Kordofan kills at least 14, including children
- Avoid Slam: Clearing the Street for the Eventual fate of Standard Size Trucks
- Find the Force of The ability to understand anyone on a deeper level: Improving Mindfulness and Connections
- Overlooked infertility care should be part of national health services, says WHO
